Worldwide Clinical Trials (“Worldwide” or the “Company”), a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization with highly complementary strengths in oncology, biometrics, and FSP capabilities, substantially enhancing Worldwide’s offerings to biopharma customers globally and expanding its employee base to approximately 4,400 across more than 70 countries.
Read the full article: Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research //
Source: https://www.businesswire.com/news/home/20260216520730/en/Worldwide-Clinical-Trials-Completes-Acquisition-of-Catalyst-Clinical-Research